louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00431535: Study Concerning Relationship Between Mixed Venous Saturation (SvO2) and Balance
Official title: Descriptive Study Concerning the Connection Between SvO2 and Orthostatic Function Post Operatively
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Surgery
Keywords: Fluid
SvO2
Mobilisation
Orthostatic function
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2007-02-06
Enrollment: 17
Sex: MALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: It is the purpose of the investigators to investigate the possible relationship between fall in the amount of Oxygen in the blood and disturbances of balance-function before and after surgery.

Detailed description: It has been shown that the mixed venous saturation (SvO2) is usable as a parameter of fluid status. It has also been suggested that there is a connection between SvO2 and blood flow in tissue , and that a SvO2 of less than 40% is a sign of tissue hypoxia.

Recently it has been shown that patients going through heart surgery experience a drop in SvO2 during early mobilization.This drop lasts throughout the mobilisation process.

We want to investigate whether the same mechanism applies to patients going through other types of surgery, and whether there is a connection between a drop in SvO2 and orthostatic function.

This will be done by making 3 tests. One pre-operatively,one six hours post-operatively and one 18-24 hours after surgery.

The tests will consist of:

1. 10 min of rest.
2. 3 min of sitting upright on the side of the bed. C. 3 min of standing on the floor. D. 10 min of rest.

Between each position a venous blood sample will be taken. Also 1 blood sample will be taken at the end of surgery.

Continuous measurements by the Finapres system wil be made throughout the test-sequence to investigate changes in BP, SV, TPR and HR.

At the same time the patient will be pain-scored when taking a new position.

Eligibility criteria: Inclusion Criteria:

* Patients going through Radical Prostatectomy, where CVC is standard.

Exclusion Criteria:

* Non informed consent
* ASA \> II
* Age less than 18, or more than 80 years
* Diabetes Mellitus
* Epidural analgetics
* Alcohol abuse (investigators assessment)
* Unable to understand written or spoken information
* Using beta-blockers

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Dept of anesthesia 2041, ABD centre, Rigshospitalet, Blegdamsvej
state: Seeland
city: Copenhagen
country: Denmark
facility: Rigshospitalet
state: Seeland
Study officials:
name: Christoffer Joergensen, M.S.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03685435: Preoperative Presence of Gastric Content in Non-fasting Patients - an Ultrasound Study
Official title: Preoperative Presence of Gastric Content in Non-fasting Patients - an Ultrasound Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Non-fasting Patients
Rapid Sequence Intubation
Anesthesia Intubation Complication
Keywords: Ultrasound
Gastric content
Non-fasting
Rapid Sequence Induction
Gastric volume
Lead sponsor: University Hospital, Akershus
Sponsor class: OTHER
First posted: 2018-09-26
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients that are assigned to rapid sequence intubation are considered non-fasting. Reasons for considering a patient non-fasting are among others: intake of food the last six hours, nausea, anxiety, preoperative intake of painkillers or reflux disease.

The ultrasound method we are using, are only valid for this specific population.

Brief summary: Using bedside ultrasound, the investigators will examine gastric content in non-fasting patients assigned to rapid sequence intubation (RSI). The procedure will be done immediately before intubation. The percentage of non-fasting patients who actually have gastric content will be determined.

Identifying gastric content is critical because presence increases the risk of pulmonary aspiration during intubation.

Detailed description: Quantitative gastric content will be registered by measuring the cross section area of antrum using bedside ultrasound. The area and the patients age will be applied to estimate gastric volume.

Eligibility criteria: Inclusion Criteria:

* adults scheduled for surgery
* Adults over 18 years old that are assigned to general anesthesia with rapid sequence intubation (RSI)

Exclusion Criteria:

* Body mass index over 40
* Pregnant women
* Patients earlier underwent gastric surgery
* Critically ill patients where spending time on ultrasound would cause a major disadvantage for the patients

Primary outcomes:
measure: High risk of aspiration
timeFrame: Immediately before intubation
measure: Low risk of aspiration
timeFrame: Immediately before intubation
Secondary outcomes:
Other outcomes:
Locations:
city: Lørenskog
country: Norway
facility: Akershus University Hospital
state: Akershus
Study officials:
affiliation: University Hospital, Akershus
name: Vegard Dahl, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05011435: Assessment of the Feasibility of Using a Smartphone Application for the Prevention and Screening of Burnout (BURNOUT ADVICE)
Official title: Assessment of the Feasibility of Using a Smartphone Application for the Prevention and Screening of Burnout
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Burnout, Professional
Lead sponsor: Weprom
Sponsor class: OTHER
Collaborators: name: Kelindi
First posted: 2021-08-18
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The population will include the first 200 users of the application who did not object to the use of their data for this assessment.

Brief summary: Burnout syndrome has been recognized as a mental illness since 2020. All workers can be affected. The consequences are multiple and often serious, ranging from stoppage of work to depression or even suicide. According to a 2019 survey by Malakoff, 56% of employees are in "professional or personal fragility", but the statistics are incomplete.

In the medical community, the burnout rate is doubled compared to the general population.

The diagnosis of pre-burnout can precede a burnout by several months, an early treatment can then reduce complications and improve the quality of life at work.

On a study model on health data already carried out as part of a cancer detection application in smokers which involved 7000 users and which showed the ability to of such an application to detect curable symptomatic cancers from questionnaires (24% with application against 9% without application), we will carry out a descriptive evaluation of the use of an application to detect pre-burnout, burnout and depressive syndrome in a worker population. In the event of a risk alert of pre-burnout, burnout or depressive syndrome, the application will display a message to the user suggesting that he consult his general practitioner or put him in contact with a doctor through a teleconsultation via a dedicated platform.

This first study will assess the feasibility and acceptability of an early detection approach among professionals of a state of "fragility" (pre-burnout, burnout or depressive syndrome). Subsequently, a larger study will evaluate the effectiveness of this application for the early detection of burnout among professionals, its management and the reduction of costs for the healthcare system and society.


Eligibility criteria: Inclusion Criteria:

* Person aged 18 to 64
* Exercising a professional activity
* User informed of the use of this data and not objecting to it

Exclusion Criteria:

* Professionals on sick leave

Primary outcomes:
measure: usefulness
timeFrame: 6 months
Secondary outcomes:
measure: alert
timeFrame: 6 months
measure: Consultation
timeFrame: 6 months
Other outcomes:
Locations:
city: Le Mans
country: France
facility: ILC
Study officials:
affiliation: ILC
name: Fabrice DENIS, Pr
role: STUDY_DIRECTOR
References:
Clinical trial NCT02714335: The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients
Official title: An Observational Study to Determine the Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients in Taiwan
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carcinoma, Non-Small-Cell Lung
Lead sponsor: National Taiwan University
Sponsor class: OTHER
Collaborators: name: GlaxoSmithKline
First posted: 2016-03-21
Enrollment: 200
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Site will retrieve tissue samples of around 200 cases of NSCLC patients with informed consent including about 100 cases of adenocarcinoma (AC) and 100 cases of squamous cell carcinoma (SCC), with stages of IB, IIA, IIB and IIIA.

Brief summary: Considering the low expression rate of Melanoma-associated antigen 3 (MAGE-A3) in Asian especially Southeast Asian, it would be great interests to investigate the potential polymorphism of MAGE-A3 in Non-Small-Cell Lung Cancer (NSCLC) patients in Taiwan. Meanwhile, it is also interesting to study the expression of Preferentially Expressed Antigen In Melanoma(PRAME) and Epidermal growth factor receptor (EGFR) mutation status as well as to find out significant factors which may affect their expression such as smoking status, histological types, tumour size and stages in Taiwan.

Detailed description: Considering the low expression rate of MAGE-A3 in Asian especially Southeast Asian, it would be great interests to investigate the potential polymorphism of MAGE-A3 in NSCLC patients in Taiwan. Meanwhile, it is also interesting to study the expression of PRAME and EGFR mutation status as well as to find out significant factors which may affect their expression such as smoking status, histological types, tumour size and stages in Taiwan

Eligibility criteria: Inclusion Criteria:

- Tissues samples up to 200 cases of NSCLS patients with informed consent, consisting of about 100 cases of adenocarcinoma (AC) and 100 cases of squamous cell carcinoma (SCC), with stage of IB, IIA, IIB and IIIA

Exclusion Criteria:

- No

Primary outcomes:
measure: Number of patients with at least one MAGE-A3 gene single nucleotide polymorphism (SNP)
timeFrame: up to 44 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01857635: Use of TpCO2 (Transcutaneous CO2 Measurement) as PaCO2 Predictor During NIV in Case of Acute Hypercapnic Respiratory Failure
Official title: Use of TpCO2 (Transcutaneous CO2 Measurement)as PaCO2 Predictor During Non Invasive Ventilation (NIV) in Case of Acute Hypercapnic Respiratory Failure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypercapnic Respiratory Failure
Keywords: Acute respiratory failure
Hypercapnia
Non invasive ventilation
Transcutaneous CO2 measurement
Lead sponsor: University of Lausanne Hospitals
Sponsor class: OTHER
First posted: 2013-05-20
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Intensive care unit patients equipped with an arterial line and requiring non invasive ventilation because of acute hypercapnic respiratory failure

Brief summary: In patients suffering from hypercapnic respiratory failure and treated by non invasive ventilation (NIV), the interest of using transcutaneous CO2 measurement to evaluate PaCO2 and PaCO2 variation over time is unknown and will be evaluated in this study. Measurements will be done during one-hour NIV treatments.


Eligibility criteria: Inclusion Criteria:

* ICU patient equipped with an arterial line
* NIV treatment prescribed by the clinician in charge
* Hypercapnia defined by PaCO2\> 42mmHg

Exclusion Criteria:

* Severe hemodynamic instability
* Severe psychiatric disorders
* Denied consent
* Age \< 18 years

Primary outcomes:
measure: Comparison between TpCO2 (transcutaneous non invasive CO2 partial pressure measurement) and PaCO2 (obtained by blood gas analysis) values during NIV treatment.
timeFrame: sixty minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Lausanne
country: Switzerland
facility: Intensive care and burn unit, University hospital of Lausanne
Study officials:
affiliation: University of Lausanne Hospitals
name: Philippe Jolliet, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04286035: Two Different Blocks for Postoperative Analgesia in Patients Undergoing Unilateral Total Knee Arthroplasty
Official title: Comparison of the Effects of Femoral Nerve Block and Adductor Canal Block on Postoperative Analgesia in Patients Undergoing Unilateral Total Knee Arthroplasty
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Knee Replacement, Total
Pain, Postoperative
Anesthesia, Regional
Keywords: femoral nerve block, adductor canal block, total knee arthroplasty
Lead sponsor: Sisli Hamidiye Etfal Training and Research Hospital
Sponsor class: OTHER
First posted: 2020-02-26
Enrollment: 70
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The frequency of femoral nerve block and adductor canal block for analgesia after TKA(total knee arthroplasty) increases with the use of ultrasonography in regional anesthesia. In this study, we aimed to compare the effects of femoral nerve block and adductor canal block on postoperative analgesia in patients undergoing unilateral knee arthroplasty.


Eligibility criteria: Inclusion Criteria:

* ASA(American Society of Anesthesiologists) Classification I-II
* Age: \<55 years
* Unilateral total knee arthroplasty

Exclusion Criteria:

* Does not approve the study
* Pregnant
* Emergency
* ASA III-IV
* History of local anesthetic allergy
* Infection in the block area
* Coagulation disorder
* Morbid obesity (body mass index\> 40 kg / m²)
* Severe organ failure
* Previous neurological deficit
* Psychiatric disease
* History of chronic pain

Primary outcomes:
measure: Tramadol consumption
timeFrame: 24 hours after operation
measure: VAS(visual analogue scale) score (0-10, 0 is no pain, 10 is the most severe pain)
timeFrame: 24 hours after operation
measure: Rescue analgesic requirement
timeFrame: 24 hours after operation
Secondary outcomes:
measure: Postoperative nausea and vomiting
timeFrame: 24 hours after operation
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: SBÜ Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi
Study officials:
References:
Clinical trial NCT06476535: Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy
Official title: Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Myeloproliferative Neoplasm
Inflammatory Disease
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2024-06-26
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: MyeloProliferative Neoplasm patients followed in one of the centres participating to the FIM (French Intergroup- MPN) group

Brief summary: The study will collect cases of MPN patients who also benefit from an anti-inflammatory immunotherapy for another disease. Efficacy and tolerability of the drug will be assessed in this population.


Eligibility criteria: Inclusion Criteria:

* MyeloProliferative Neoplasm diagnosis
* receiving or having received an immunotherapy targeting IL-1, IL-6, IL-17, IL-23 or TNF

Exclusion Criteria:

* Unable to consent

Primary outcomes:
measure: Efficacy of the anti-inflammatory immunotherapy
timeFrame: 1 year
measure: Tolerability of the anti-inflammatory immunotherapy
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: Chu Brest
Study officials:
References:
Clinical trial NCT02641535: Evaluating the Physiological Strain Induced by a BC Membrane Protective Garment Under Exercise-heat Stress Compared to a Protective Coverall
Official title: Evaluating the Physiological Strain Induced by a BC Membrane Protective Garment Under Exercise-heat Stress Compared to a Protective Coverall
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Physiological Stress
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2015-12-29
Enrollment: 12
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Israel ministry of defense is examining a new BC membrane protective garment of BLAUER company constructed with GORE CHEMPAK fabric for the border guard of the police forces. The goal of this research is to perform a comparative experiment in order to evaluate the physiological strain induced by the new protective garment under exercise-heat stress conditions, compared to protective garment in current use.

Detailed description: In order to physiologically evaluate a new BC membrane protective garment for the Israeli police use under exercise-heat stress conditions, 12 healthy volunteers from the border guard will participate in this study.

The subjects will undergo 4 experiment days: Recruitment day, one day of acclimatization to heat, and 2 days of performing experiment protocol, each day dressed with different protective garment (Protective garment in current use + NBC mask, new BC membrane protective garment + NBC mask).

Core (rectal) and skin temperature and heart rate will be monitored continuously, liquid balance will be recorded.the physiological heat strain will be assessed and compared between the different protective garments.

Eligibility criteria: Inclusion Criteria:

* Aged 18-40 years.
* Healthy civilian volunteers.
* Without known medical illness or medication use.

Exclusion Criteria:

* The existence or suspicion of existing cardiac or respiratory disease.
* Hypertension.
* Diabetes.
* Psychiatric condition.
* Any muscles or skeleton condition.
* Any hormonal disease or any other chronic illness that may inhibit participation in the experiment.
* Infectious disease 3 days prior to the experiment.

Primary outcomes:
measure: physiological strain (composite)
timeFrame: 3 days for each participant
Secondary outcomes:
measure: Rectal temperature
timeFrame: 3 days for each participant
measure: Skin temperature
timeFrame: 3 days for each participant
measure: Heart rate
timeFrame: 4 days for each participant
measure: Sweat rate (composite)
timeFrame: 3 days for each participant
Other outcomes:
Locations:
city: Tel-Hashomer
country: Israel
facility: Sheba medical center
state: Ramat- Gan
Study officials:
affiliation: Sheba Medical Center
name: Ofir Frenkel, M.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01056835: Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy
Official title: Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Chronic Allograft Nephropathy
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2010-01-26
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the effect of Prostaglandin I2 analogue use on the development of chronic allograft nephropathy and changes in allograft function in prevalent renal transplant recipients


Eligibility criteria: Inclusion Criteria:

* prevalent renal transplant recipients 2 years after transplantation
* no history of acute rejection
* stable renal function

Exclusion Criteria:

* history of biopsy-proven chronic allograft nephropathy
* history of biopsy-proven CNI nephrotoxicity
* history of biopsy-proven or clinical acute rejection
* unstable trough level of CNI or extremely low level of CNI
* bleeding tendency(+)
* pregnancy or pregnant-willing
* anticoagulation(+)
* antiplatelet agent (+)
* significant comorbidity(+): Acute coronary syndrome, pneumonia

Primary outcomes:
measure: graft pathology, serum creatinine, creatinine clearance, eGFR
timeFrame: 1 year after drug administration
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University
name: Jongwon Ha, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: